Renaissance BioScience

Overview
News
Biopesticides?
Product stageSegments
Go-to-Market
?
Microbial Pesticides
?

Renaissance BioScience Corp. is a leading bioengineering company based in Vancouver, Canada. Its core technology involves developing non-GMO, organic-suitable yeast strains that offer innovative solutions across various sectors, including agriculture, food and beverage, animal health, and energy.

One of Renaissance's flagship products is a proprietary yeast strain that reduces acrylamide formation, a probable carcinogen found in carbohydrate-rich foods like potatoes, grains, and baked goods. Marketed under brand names like Acryleast, Acryleast Pro, and Acrylow, this yeast can naturally lower acrylamide levels by up to 90% in food products without disrupting manufacturing processes. The company has secured patents for this acrylamide-reducing technology in several major markets worldwide.

Additionally, Renaissance has pioneered a groundbreaking yeast-based platform for producing and delivering RNA bioactive molecules, including RNAi-based biopesticides. This technology addresses key challenges in RNA delivery, such as stability, cost-effective manufacturing, adaptability, and safety. The company secured a patent in China for this RNA production and delivery platform, bolstering its robust IP portfolio.

Renaissance's RNAi biopesticides leverage RNA interference to selectively inhibit crucial proteins in target pests, providing a precise and environmentally sustainable approach to crop protection. The company received regulatory approval from Health Canada to conduct field studies, marking a significant milestone in its biopesticide development pipeline.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
Vancouver BC CAN
Founded year:
2013
Employees:
11-50
IPO status:
Private
Total funding:
USD 939.1 k
Last Funding:
USD 172.0 k (Grant; Feb 2024)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.